SKYE Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases...

Stats
Dagens volum	34 863.00
Gjennomsnittsvolum	46 458.00
Markedsverdi	12.65B
EPS	$0 ( 2024-03-31 )
Neste inntjeningsdato	( $0 ) 2024-05-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.150
ATR14	$0.0560 (0.43%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-13	5am Partners Vii, Llc	Buy	450 000	Common Stock
2024-03-13	Schwab Andrew J.	Buy	450 000	Common Stock
2024-02-29	Grayson Paul A.	Buy	100 000	Common Stock
2024-02-29	Grayson Paul A.	Buy	35 000	Stock Option (Right to Buy)
2024-02-29	Charych Deborah H.	Buy	35 000	Stock Option (Right to Buy)

INSIDER POWER
98.76
Last 83 transactions
Buy: 1 749 377 489 \| Sell: 16 641 486

Volum Korrelasjon

Lang: -0.42 (neutral)

Kort: 0.47 (neutral)

Signal:(53.944) Neutral

Skye Bioscience, Inc. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Skye Bioscience, Inc. Korrelasjon - Valuta/Råvare

0.06
( neutral )

-0.20
( neutral )

0.00
( neutral )

0.14
( neutral )

0.00
( neutral )

0.25
( neutral )

Skye Bioscience, Inc. Økonomi

Annual	2022
Omsetning:	$0
Bruttogevinst:	$-114 998 (0.00 %)
EPS:	$-9.82

FY	2022
Omsetning:	$0
Bruttogevinst:	$-114 998 (0.00 %)
EPS:	$-9.82

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.0200

FY	2020
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.0300

Financial Reports:

No articles found.

Skye Bioscience, Inc.

Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.